Loading
companiesCompany
Generate:Biomedicines
Generative-AI protein design company (Flagship) that went public in 2026 and is testing an antibody that neutralises leaked ADC payload to reduce side effects.
Overview
Generate:Biomedicines went public in early 2026 (~$400M IPO). Oncology programmes: GB-4362, an MMAE neutraliser with FDA Fast Track for enfortumab vedotin toxicity in urothelial cancer (trial-in-progress at ESMO 2026), and GB-5267, a MUC16 CAR-T with Roswell Park. First AI-designed antibody advanced to phase 3 in a non-oncology indication.
Headquarters
Somerville, MA, US
Scorecard
All companies#162of 1244 companies, score 36
- approved products +6
- targets +2
- modalities +2
- regions +5
- 24-month regulatory events +4
- registry trials +17
1 approved, 0 in phase 3, 0 earlier, 1 targets, 73 registry studies. Formula on the scorecards page.
Funding
All startupsPublic
Investors
Type
AI & software · GBIO
Stage
Public
Website
ApprovedADC
Enfortumab vedotin · Padcev
Enfortumab vedotin is an ADC against Nectin-4 that, combined with pembrolizumab, nearly doubled survival in advanced bladder cancer.
Similar pages
- CompanyIsomorphic Labs
Shares AI-designed proteins that grip the floppy parts of cancer drivers, De novo designed protein binders, Drug discovery roadmap: screening in mice → maps of dependency → designing in silico, AI-driven drug & target discovery and the tag frontier.
- CompanyArsenal Biosciences
Shares CAR-T cell therapy, Ovarian cancer and the tag frontier.
- TechnologyTrained innate immunity
Shares Bladder & urothelial cancer and the tag frontier.
- TechnologyDegrader-antibody conjugate (DAC)
Shares Drug discovery roadmap: screening in mice → maps of dependency → designing in silico and the tag frontier.
- CompanyAktis Oncology
Shares Bladder & urothelial cancer and the tag frontier.
- TechnologySystematic drug repurposing
Shares AI-driven drug & target discovery and the tag frontier.
- TechnologyOligonucleotide therapeutics
Shares Drug discovery roadmap: screening in mice → maps of dependency → designing in silico and the tag frontier.
- TechnologyArmoured, logic-gated & next-gen CARs
Shares CAR-T cell therapy and the tag frontier.
cancers
fronts
technologies
drugs
ApprovedADC
Enfortumab vedotin · Padcev